Phio PharmaceuticalsPHIO
13F holders, Q1 2025 (March 31)11holders
3new positions
3sold out
$1.30avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings, unchanged from Q4 2024. 3 opened new positions and 3 sold out. The largest holders were Geode Capital Management, LLC ($54K), Cetera Investment Advisers ($50K) and XTX Topco Ltd ($14K).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $68K |
| Exits | 3 | $230K |
All 13F filers, Q4 2024 → Q1 2025: 79,024 shares bought and 132,447 shares sold, net −53,423 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | New | 41,586 | $54K |
| Cetera Investment Advisers | 0.00% | Add +196.2% | 38,500 | $50K |
| XTX Topco Ltd | 0.00% | New | 10,800 | $14K |
| Morgan Stanley | 0.00% | Add +1.5% | 6,000 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -46.6% | 2,501 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Add +1436.5% | 968 | $1K |
| Assetmark, Inc. | 0.00% | New | 110 | $143 |
| UBS Group AG | 0.00% | Reduce -95.7% | 103 | $134 |
| Bank of America Corp. | 0.00% | Add +485.7% | 41 | $53 |
| Activest Wealth Management | 0.00% | No change | 9 | $12 |
| Barclays PLC | 0.00% | Reduce -97.5% | 5 | $7 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.